Ivana Magovcevic-Liebisch

Ivana Magovcevic-Liebisch, PhD, JD, serves as a Board Member at Acrivon Therapeutics, Inc. since February 2024 and is the Chief Executive Officer and President of Vigil Neuroscience since July 2020. Additionally, Magovcevic-Liebisch is an Advisory Board Member at Convergence Forum, a Board Member at Aeglea BioTherapeutics (2018-2023), AbSci (2020-2023), and AGTC (2014-2022). Previous roles include EVP and Chief Business Officer at Ipsen (2018-2020), Executive Vice President at Axcella (2017-2018), SVP and Head of Global Business Development at Teva Pharmaceuticals (2013-2017), and EVP and Chief Operating Officer at Dyax Corp (2001-2013). Magovcevic-Liebisch holds a PhD in Genetics from Harvard University, a JD in High Technology Law from Suffolk University Law School, and a BA in Biology & Chemistry from Wheaton College Massachusetts.